South Africa's third-largest pharma manufacturer scaling regulatory and supply-chain operations
Cipla Africa manufactures pharmaceuticals across public and private sectors in South Africa, with a tech stack anchored in SAP, Power BI, and SQL—typical of regulated manufacturing but signaling heavy reliance on legacy enterprise systems. Active projects span new-market launches, vendor compliance, and regulatory dossier management, while pain points cluster around approval delays and process automation gaps. Hiring is decelerating across quality, logistics, and regulatory roles, suggesting a company in operational stabilization rather than scaling mode.
Cipla Africa is the third-largest pharmaceutical manufacturer in South Africa, producing medicines for both public and private healthcare sectors. The company operates from Cape Town and employs 201–500 people across manufacturing, regulatory, quality assurance, supply-chain, and commercial functions. Current operational focus includes new product launches into regional markets, vendor audits and GMP compliance, and digital transformation of regulatory workflows—areas where manual dossier management and approval timelines remain significant operational constraints.
SAP for enterprise resource planning, Power BI for analytics, SQL for data, and Microsoft Office suite (Word, Excel, Outlook, PowerPoint, SharePoint, Power Automate) for workflow and collaboration.
Regulatory approval delays, vendor GMP compliance, complex dossier management across markets, and automation of submission-timeline forecasting. New-market launches and process digitization are active priorities.
Other companies in the same industry, closest in size